Ultra-fast acting insulin analogues

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 8, Issue 2, 2014, Pages 117-123

  Kalra, Sanjay ^a   Gupta, Yashdeep ^b  

^a Bharti Hospital and Bharti Research Institute of Diabetes and Endocrinology   (India)

^b GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Aspart; Diabetes mellitus; Fast acting insulin aspart; Insulin; Insulin analogues; Insulin technique; Ultra fast insulin

Indexed keywords

ARGININE; EXCIPIENT; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN LISPRO; NICOTINAMIDE; PIG INSULIN; POLYMER; SHORT ACTING INSULIN; ZINC; ANTIDIABETIC AGENT;

DRUG ABSORPTION; DRUG DELIVERY SYSTEM; HUMAN; INJECTION SITE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; DIABETES MELLITUS; DRUG ADMINISTRATION ROUTE; MEDICINAL CHEMISTRY; PATENT; PROCEDURES;

CHEMISTRY, PHARMACEUTICAL; DIABETES MELLITUS; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; EXCIPIENTS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, SHORT-ACTING; PATENTS AS TOPIC;

EID: 84905666110     PISSN: 18722148     EISSN: 22123334     Source Type: Journal    
DOI: 10.2174/1872214808666140714112644     Document Type: Review

References (48)

1. Swan KL, Dziura JD, Steil GM, Voskanyan GR, Sikes KA, Steffen AT, et al. Effect of age of infusion site and type of rapid -acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy. Diabetes Care 2009: 32(2): 240-244.
2. Swan KL, Weinzimer SA, Dziura JD, Steil GM, Voskanyan GR, Steffen AT, et al. Effect of puberty on the pharmacodynamic and pharmacokinetic properties of insulin pump therapy in youth with type 1 diabetes. Diabetes Care 2008: 31(1): 44-46.
3. Luijf YM, van Bon AC, Hoekstra JB, DeVries JH. Premeal injec-tion of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care 2010; 33(10): 2152-2155.
4. Hirsch, IB. Insulin Analogues. NEJM 2005; 352(2): 174-183.
5. MannKind Corporation. Technosphere technology versatile drug delivery platform. Available at: http://www.mannkindcorp.com/ Collateral/Documents/English-US/101LR-TechnosphereTechTeaser-01.19.11.pdf (Accessed on: July 3, 2014).
6. Phillips NB, Whittaker J, Ismail-Beige F, Weiss MA. Insulin fibril-lation and protein design: Topological resistance of single-chain analogs to thermal degradation with application to a pump reservoir. J Diabetes Sci Technol 2012; 6(2): 277-288.
7. Krasner A, Pohl R, Simms P, Pichotta P, Hauser R, De Souza E. A review of a family of ultra-rapid-acting insulins: Formulation development. J Diabetes Sci Technol 2012; 6(4): 786-796.
8. Heinemann L, Nosek L, Flacke F, Albus K, Krasner A, Pichotta P, et al. U-100, pH-Neutral formulation of VIAject(®): Faster onset of action than insulin lispro in patients with type 1 diabetes. Diabetes Obes Metab 2012; 14(3): 222-227.
9. Steiner S, Hompesch M, Pohl R, Simms P, Flacke F, Mohr T, et al. A novel insulin formulation with a more rapid onset of action. Dia-betologia 2008; 51(9): 1602-1606.
10. Hompesch M, McManus L, Pohl R, Simms P, Pfutzner A, Bulow E, et al. Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin. J Diabetes Sci Technol 2008; 2(4): 568-571.
11. Heinemann L, Hompesch M, Flacke F, Simms P, Pohl R, Albus K, et al. Reduction of postprandial glycemic excursions in patients with type 1 diabetes: A novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin. J Diabetes Sci Technol 2011; 5(3): 681-686.
12. Clinical Trials. Available at: http://www.novonordisk-trials.com/ WebSite/Search/trialSearchResult.aspx?Command=Search&Sort By=StartDate&SearchTerms=FIAsp&ConditionCategory=192. (Accessed on: February16, 2014).
13. Biochaperone insulin (HinsBet). Available at: http://www. biocentury.com/products/biochaperone_insulin. (Accessed on: Feb-ruary16, 2014).
14. Muchmore DB, Vaughn DE. Accelerating and improving the consistency of rapid- acting insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using re-combinant human hyaluronidase. J Diabetes Sci Technol 2012; 6(4): 764-772.
15. Okbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 2006; 114(2): 230-241.
16. Vaughn DE, Yocum RC, Muchmore DB, Sugarman BJ, Vick AM, Bilinsky IP, et al. Accelerated pharmacokinetics and gluco-dynamics of prandial insulins injected with recombinant human hyaluronidase. Diabetes Technol Ther 2009; 11(6): 345-352.
17. Hompesch M, Muchmore DB, Morrow L, Vaughn DE. Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after co-administration of prandial insulins with hyaluronidase. Diabetes Care 2011; 34(3): 666-668.
18. Hompesch M, Muchmore DB, Morrow L, Ludington E, Vaughn DE. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. Diabetes Technol Ther 2012; 14(3): 218-224.
19. Vaughn DE, Muchmore DB. Use of recombinant human hyaluron-idase to accelerate rapid insulin analogue absorption: Experience with subcutaneous injection and continuous infusion. Endocr Pract 2011; 17(6): 914-921.
20. Morrow L, Muchmore DB, Ludington EA, Vaughn DE, Hompesch M. Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recom-binant human hyaluronidase in healthy volunteers. Diabetes Tech-nol Ther 2011; 13(10): 1039-1045.
21. Raz I, Weiss R, Yogorchikov Y Bitton G, Nagar R, Pesach B. Effect of a local heating device on insulin and glucose pharmacoki-netic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. Clin Ther 2009; 31(5): 980-987.
22. Cengiz E, WeinZimer SA, Sherr JL, Tichy E, Martin M, Carria L, et al. Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. Pediatr Diabetes 2013; 14(3): 168-173.
23. Heinemann L, Muchmore DB. Ultrafast acting insulins: State of the art. J Diabetes Sci Technol 2012; 6(4): 728-742.
24. Harvey AJ, Kaestner SA, Sutter DE, Harvey NG, Mikszta JA, Pettis RJ. Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs. Pharm Res 2011; 28(1): 107-116.
25. Sanyal T, Ghosh S, Chowdhury S, Mukherjee S. Can a faulty injection technique lead to a localized insulin allergy?. Indian J Endocr Metab 2013; 17 (Suppl 1): 358-359.
26. Mokta JK, Mokta KK, Panda P. Insulin lipodystrophy and lipo-hypertrophy. Indian J Endocr Metab 2013; 17(4): 773-774.
27. Vaag A, Pedersen KD, Lauritzen M, Hildebrandt P, Beck-Nielsen H. Intramuscular versus subcutaneous injection of unmodified insulin: Consequences for blood glucose control in patients with type 1 diabetes mellitus. Diabetic Med 1990; 7(4): 335-342.
28. Thow JC, Johnson AB, Fulcher G, Home PD. Different absorption of isophane (NPH) insulin from subcutaneous and intramuscular sites suggests a need to reassess recommended insulin injection technique. Diabetic Med 1990; 7(7): 600-602.
29. Fisher JN, Shahshahani MN, Kitabchi AE. Diabetic ketoacidosis: Low-dose insulin therapy by various routes. N Engl J Med 1977; 297(5): 238-241.
30. Rave K, Potocka E, Heinemann L, Heise T, Boss AH, Marino M, et al. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab 2009; 11(7): 715-720.
31. Pfützner A., Forst, T. Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism. Expert Opin Drug De-liv 2005; 2(6): 1097-1106.
32. Rosenstock J, Lorber DL, Gnudi L, Howard CP, Bilheimer DW, Chang PC, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: A multicentre randomised trial. Lancet 2010; 375(9733): 2244-2253.
33. Rosenstock J, Lorber DL, Gnudi L, Howard CP, Bilheimer DW, Chang PC, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: A multicentre randomised trial. Lancet 2010; 375(9733): 2244-2253.
34. Hemmingsen, P.K.H., Jensen, S. Preparation comprising insulin, nicotanamide and arginine. WO2013186138 (2013).
35. Olsen, H.B, Havelind, S., Ribel-Madsen, U., Sturis, J., Naver, H., Schlein, M., Luduigsen, S. Preparation comprising insulin, nicotinamide an aminoacid. US20130281364 (2013).
36. Pohl, R., Li, M., Wilson, B.R. Magnesium compositions for modulating the pharmacodynamics and pharmacokinetics of insulin analog, and injection site pain. WO2013158618 (2013).
37. Pohl, R., Hauser, R., Li, M., Wilson, BR. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain. US20140113856 (2014).
38. Prestrelski, S., Scott, N. Formulations for the treatment of diabetes. WO2013067022 (2013).
39. Weiss, M. Non-standard insulin analogues. WO2013010048 (2013).
40. Vanglin, D.E., Muchmore, D.B, Frost, G.I. Continuous Subcutaneous insulin infusion methods with a hyaluron-degrading enzyme. US20130022592 (2013).
41. Frost, G.I., Bilinsky, I., Vaughn, D., Sugarman, B. Super-fast-acting insulin compositions. US8568713 (2013) & EP2705850 (2014).
42. Boss, A.H., Petrucci, R., Howard, C, Mann, A. Use of ultrarapid acting insulin. US20120122775 (2012).
43. Richardson, P., Baughman, R.A., Potocka, E., Boss, A.H., Petrucci, R. Method of treating diabetes type 2 by administering ultrarapid acting insulin. US8623817 (2014).
44. Havelund, S., Jonassen, I., Olsen, H.B., Ribel-Madsen, U. Fast-acting insulin in combination with long-acting insulin. WO2012080320 (2012).
45. Weiss, M. Insulin analogues containing penta-fluoro-phenylalanine at position B24. US20140128319 (2014).
46. Spaan N, Teplova A, Stam G, Spaan J, Lucas C. Systematic review: Continuous intraperitoneal insulin infusion with implantable insulin pumps for diabetes mellitus. Acta Diabetol 2014; 51(3): 339-351.
47. Kalra S, Kalra B, Agrawal N, Khare S. Recent patents on oral insulin. Recent Pat Endocr Metab Immune Drug Discov 2010; 4(3): 248-252.
48. Iyer H, Khedkar A, Verma M. Oral insulin - a review of current status. Diabetes Obes Metab 2010; 12(3): 179-185.